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Immunoprophylaxis to limit a hepatitis B 
epidemic among women undergoing 
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Women (175) ~t ho paJ ttt tpated m an m v i t ro /e l  tthzatton (I1/F) proql amnw ~t el e pos stbh' 
evposed to hepatttts B UIlUS Late1 tt became evtdent hat 79 ~tolnen had a hepatttt~s B 
refection. 49 were exposed but not infected and 47 were not exposed Hepatm~ B 
tmmunoglobulln (HBlg) and recombmant hepatitis B vaccine (HBvaxDNA) were offered 
to all women and partners except for those wtth estabhshed hepatttts B Women were 
gwen an 'lntenswe' schedule of  HBIg (0, I months) and vaccine (0, 1, 2, 6 months) Spouses 
received HBIg (0, 1 months) and raceme (0, 1, 6 months) Blood samples were taken at 
the time of  dtagnosts of  the HBV epldemtc and at regular mtervaIs Hospttal personnel 
immunized according to the regular schedule (0, 1 and 6 months) wtth HBvaxDNA but 
wtthout HBlg served as controls During the observation pertod of  7 months antt-HBc 
~eroconverston was not observed At month 7 the seroconverston rate for males was 89%, 
slgmficantly lower than that Jor females (100%) Intermedtate rates were Jound for the 
control groups (94%) Stgntficant differences in geometrw mean tltre between IVF-treated 
patients and controls were, however, observed at month 7 (551 mlU ml-1 jor female 
pattents versus 1582 mlUml  -x for thetr controls and 171 mlUml - l  for males versus 
899 mlU ml-1 for their controls) Possible explanatlons Jor the low reactwlty to HBsAg 
vaccine are discussed 
Kevwords Hepatttr, B postexpo',ure prophyla),r, pd',Sr, C actlxe irnmumzatlon 
INTRODUCTION 
In early March 1988 the University Hospital Dljkzlgt 
was confronted with a hepatitis B epldemm in women 
who had undergone m wtro fertilization I 2 All women 
(n= 175) who had undergone m vttro fertlhzatlon (IVF) 
since November 1987 but were without signs of hepatitis 
B virus (HBV) infection at first screening, as well as their 
sexual partners, were offered passwe active immunization 3 
The rationale for starting passive active lmmumzation 
6 18 weeks after HBV-exposure was to modify Infection 
in females and to prevent infection in males All women 
followed an 'intensive' immunization scheme consisting 
of hepatitis B lmmunoglobuhn (HBIg) on day 1 and 1 
month later and recombinant vaccine on day 1 and 1, 2 
and 6 months later Male partners who may have been 
exposed to HBV for several weeks also received HBIg 
on day 1 and 1 month later and recombinant vaccine on 
day 1 and 1 and 6 months later 
In this study the levels of HBV protective antibodies 
(antl-HBs ~> 10mlU ml -x) induced by passive active 
immunization were examined An explanation was 
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sought for the relatively poor immune response m the 
IVF population 
MATERIALS  AND METHODS 
Patients and controls 
From 2 November 1987 until 2l January 1988 175 
women undergoing 1VF might have been exposed to 
hepatitis B virus Tissue culture medium supplemented 
with 7 5% heat-inactivated (30 mln 56°C) human serum, 
which was used for pre-embryo cultures or other 
procedures during in wtro fertlllzatmn, seemed to be the 
most probable source of infection The human serum was 
regularly pooled from blood samples of 15-20 pregnant 
women All donors were individually screened for 
hepatitis B virus Due to a breakdown m communication 
between the outpatient chnlc of the Department of 
Obstetrics and the IVF laboratory, the results of the 
routine screening of sera from pregnant women for 
HBsAg temporarily did not reach the IVF laboratory 
and an HBV-posJtlve serum was apparently included in 
the pooled serum On 2 March 1988 the epidemic was 
discovered by reports on three cases of jaundice All 
women at risk and their partners were Immediately 
requested to visit the University Hospital Dljkzlgt for 
medical examination Blood samples were obtained from 
174 potentially exposed women and 167 sexual partners 
and preventive measures were advised These measures 
Table 1 Overvtew of the vaccination groups after possible exposure 
to hepatths B 
Group 
2 3 4 
Females Males Total 
Total 128 (27) 47 (14) 79 96 350 
Excluded at presentation" 32 (13) 0 1 8 41 
Vaccination started 96 (14) 47 (14) 78 88 309 
Excluded after screemng ~ 58 (8) 6 (1) 4 11 79 
Vaccination continued 38 (6) 41 (13) 74 77 230 
Vaccmatton complete 29 (6) 30 (8) 56 65 180 
Blood sample month 7 24 (3) 29 (8) 43 52 148 
Evaluated month 7 ~ 22 (3) 28 (8) 43 52 145 
Figures in parentheses mdtcate number of women pregnant 
'Chmcal hepatlhs pregnant and HE}sAg + known immune response 
after vaccination no serum avadable, ~markers of past or present HBV 
mfechon w~th or wtthout confirmatton by pre-treatment sera, Csee text 
for reasons for excluston 
Included hygiene, use of condoms during sexual mter- 
course and passtve active lmmumzatlon 
Analysis of the mcldence of HBV mfectlon in 7 day 
cohorts of m wtro fertlhzatlon treatment finally revealed 
that the period of mfectlous exposure only extended from 
2 November to 13 December 1987 (period ! ), thts period 
comctded with the use of one of the two batches of pooled 
serum used m tissue culture None of the women treated 
from 14 December 1987 to 21 January 1988 (period 2) 
developed signs of a hepatitis B infection 
Of the total of 175 women, 128 were exposed to the 
lnfecttous batch of pooled serum, the remamlng 47 
women were not exposed to infectious culture medtum 
Of the 128 women exposed m period 1, 30 had chnlcal 
stgns of HBV or were HBsAg-poslttve and pregnant at 
first presentaUon One woman did not dehver serum and 
another woman was protected by previous vaccmauon 
Therefore lmmuntzatlon was started m 96 women Due 
to the presence of markers of hepatitis B m the pre-IVF 
serum (9 cases) or in serum taken at first presentatton 
(49 cases), tmmuntzatlon was stopped in 58 of the 96 
women (Table 1) The remamlng 38 women contmued 
tmmuntzatlon and may be charactertzed asexposed but 
not infected (group 1) A second group of vaccmees 
(group 2) ts composed of women who recetved IVF 
treatment m period 2, the mformat~on that the culture 
medium used m period 2 was not Infectious became 
available about 2 months after immunization had started 
lmmunlzatton was completed m the large majority of 
women The other lmmuntzatton groups comprised the 
partners The spouses of 79 HBV infected women by IVF 
treatment were labelled as group 3 The spouses of 49 
non-infected women from period I together with the 
spouses of 47 women treated in pertod 2 comprtsed group 
4 Further details of the four lmmunlzatton groups are 
given m Tables I and 2 The control groups, hospital 
personnel tmmuntzed m the same pertod, conststed of 84 
females (group 5) and 53 males (group 6) 
Immunization 
Hep,lt]t]s B Immunoglobuhn (5ml, 100 200 IU ant]- 
H Bs ml l, Central Laboratory of the Netherlands Red 
Cross Blood Transfusion Service (CLB)) and hepatitis B 
recombinant vaccine (10 l~g, HBvaxDNA, Merck Sharp 
& Dohme, West Point, PA, USA) were administered to 
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all women except hose wtth chnlcal hepatttlS or pregnant 
women with HBsAg-posltlvtty, as determined by rapid 
blood testing with the reversed passive haemagglutmatton 
assay (Hepatest, Wellcome Laboratories, Beckenham, 
UK) at first presentation A second dose of HBIg was 
gtven 1 month later Additional doses of vaccme were 
admmtstered 1, 2 and 6 months later HBIg and vaccine 
were dtscontlnued as soon as HBV markers not due to 
HBIg or vaccine were detected in the serum 
Male partners recetved HBlg on day 1 and 1 month 
later and HBvaxDNA (10#g) on day 1 and 1 and 6 
months later Immuntzatlon was dtscontlnued when 
vacclnees were found to be poslttve for HBsAg, antt-HBc 
or antt-HBs at screening After 4 months, partners of 
HBV-poslttve women (group 3) received an addttlonal 
dose of HBIg if the antl-HBs tttre was below 20 mIU ml- 
and hkely to fall below 10 mIU ml- 1 before the booster 
vaccine injection at 6 months 
Hospital personnel, who served as controls, recetved 
HBvaxDNA (10/~g) from the same lot according to the 
regular schedule on day 1 and 1 and 6 months later 
without HBIg (Table 2) HBIg was admmtstered by 
lnjectton] m rata the buttock, HB-vacclne was injected 
1 m into the deltoid muscle 
Blood sampling and laboratory methods 
Pre-lmmuntzatton serum samples were obtained m 
March 1988 For females follow-up blood samples were 
drawn 1,2, 6 and 7 months after the first vaccme ln lectlon 
For males, blood samples were taken after 1, 4, 6 and 7 
months All pre-lmmuntzatton samples from groups 1 4 
as well as follow-up samples were tested for HBsAg, 
antl-HBc and antl-HBs Blood samples from controls 
were tested for antl-HBc and antI-HBs after 7 months 
Blood samples were tested for HBsAg and antl-HBc 
by enzyme tmmunoassay (Abbott Laboratortes, Chtcago, 
IL, USA) Antl-HBs was tested by radio lmmunoassay 
(Ausab, Abbott Laboratories) and quantified using the 
WHO standard preparahon 4 A protective antt-HBs level 
was defined as ant]-HBs concentration ~> 10 mlU ml -~, 
in the absence of other HBV markers 
Statistical calculations 
Stattstlcal differences in protective antl-HBs levels were 
Table 2 Characteristics of IVF treated females, partners and controls 
completing hepatltts B vaccmatton 
Vaccination schedule 
m months 
Mean age HBIg HBvaxDNA 
Group No (range) 0, 1 0, 1 6 0, 1 2 6 
1 Women exposed 22 35 (28 39) x 
2 Women 28 35 (24 40) x 
not exposed 
3 Partners 43 39 (32 57) x"  × 
HBV refection 
4 Partners no 52 38 (29 48) × ~ x 
HBV mfechon 
5 Female controls 84 34 (22 57) × 
6 Male controls 53 35 (22 61) x 
aMales with ant~-HBs levels below 20 mlU m1-1 at month 4 received an 
additional HBIg injection 
bSexual partner exposed but not infected (n = 20) and sexual partner not 
exposed (n = 32) 
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calculated with 95% confidence intervals for the difference 
between two proportions The geometric mean tltres 
(GMTs) for all vacclnees in various groups were 
compared, after logarithmic transformation by the 
Student's t-test 
RESULTS 
Of the 230 individuals who continued immunization after 
initial screening (79 females, 151 males), a total of 180 
vacclnees (59 females, 121 males) completed the immuniz- 
ation programme Postlmmunlzatlon blood samples were 
obtained in 148 cases (53 females, 95 males) at month 7 
Three women (2 in group l and l in group 2) were 
excluded from evaluation because they showed more than 
l0 mIU ml- ~ antl-HBs on day l, although antl-HBc tests 
were negaUve 
Of the 38 females exposed to HBV (group 1 ), three did 
not show up for further treatment after month 1 At that 
Ume, they were all negaUve for both HBsAg and 
anU-HBc Two females dtd not return for follow-up at 
month 6 but were HBsAg-negatlve and anU-HBs-posiUve 
at month 4, another nine women who were HBsAg- 
negative at month 6 w~th antl-HBs >~ 10 mIU ml- ~ did 
not appear for follow-up at month 7 Of the 37 women 
who delivered healthy hvlng children 5, nine received one 
dose of HBIg and HBvaxDNA during pregnancy and 14 
received full immunization during pregnancy No adverse 
reactions to HBIg or vaccine were reported during the 
observation period of 7 months for vaccmees w~th or 
w~thout HBV markers at the ttme of first presentation, 
except for one pregnant vacclnee who had a spontaneous 
abortion two days after initial immunization 
The rate of development of protecUve anubody levels 
(~> 10 mIU m1-1) is shown m Table 3 One month after 
the first dose of HBIg and vaccine, protective anubodles 
were found in 99% (203/205) of the vaccmees Anti-HBs 
levels were inadequate m two cases (one female m group 
2 with 8 mIU ml-1 and one male m group 3 with no 
detectable antl-HBs) At month 2 protective antibody 
levels were demonstrated in all females tested At month 
4 23% of the men of group 3 and 20% of those of group 4 
were unprotected (antl-HBs < l0 mlU ml- 1) At month 
6 protective antl-HBs levels were measured significantly 
less often m group 4 males (48%, 95%CI 36 60%) 
compared with both groups l and 2 (87%, 95%CI 
75-99%) and group 3 (81%, 95%CI 71 91%) due to 
the fact that the antl-HBs level of the majority of the 
Table 3 Development of protectwe anhbody levels (anh-HBs 
>~ 10 mlU ml - 1) after vaccmahon 
Percentage with anh-HBs >~10 mlU m1-1 
Month 
Group Sex 1 2/4 a 6 7 
1 Female 100 (33) 100 (33) 87 (31) 100 (22) 
2 Female 97 (39) 100 (39) 87 (31) 100 (28) 
3 Male 98 (61) 77 (57) 81 (58) 93 (43) 
4 Male 100 (72) 80 (64) 48 (68) 86 (52) 
5 Female 94 (84) 
6 Male 94 (53) 
aBIood sample females at month 2, males at month 4 
F~gures m parentheses indicate number of blood samples tested 
T~ble 4 Levels of anti-HBs after HB-vaccmatlon expressed as geo- 
metric mean tltre m mlU ml-  ~ calculated for vaccmees with anti-HBs 
~> 1 mlU m1-1 
Group Sex 
GMTm mlUml -  
Month 
1 2 4 a 6 7 
1 Female 35 (33) 45 (33) 30 (29) 396 (22) 
2 Female 35 (38) 47 (39) 44 (30) 715 (28) 
3 Male 34 (60) 16 (56) 16 (56) 150 (43) 
4 Male 37 (72) 19 (65) 9 (65) 190 (50) 
5 Female 1582 (80) 
6 Male 899 (50) 
'Blood sample females at month 2, males at month 4 Figures 
m parentheses mdtcate number of blood samples wpth anh-HBs 
1 mlU ml ' anh-HBs 
p values for differences in GMT at month 7 group 1 versus 2, not 
sfgmficant, group 3 versus 4, not sfgmficant, group 5 versus 6, not 
stgmficant, group 1+2 (GMT=551mlUm1-1) versus 3+4 (GMT= 
171 mlU ml-1), p<0002,  group 1+2 versus 5, p=0001,  group 3+4 
versus 6, p<0 001 
vacclnees in group 4 remained just below the arbitrarily 
chosen level of 10 mIU ml- 1 (see GMTs at month 6 in 
Table 4) For group 3 the higher ate of 81% was probably 
due to the extra dose of HBIg given at month 4 to 25 
spouses with antt-HBs tltres < 20 mIU ml- 1 Protective 
antl-HBs levels after completion of vaccmatlon at month 
7 were found in all women of groups 1 and 2 (100%) 
whereas the percentage of males m groups 3 and 4 
together 07=95) with protective antibodies at month 7 
was 89% (95%C1 83 95%) 
Table 4 shows the geometric mean tltres of antl-HBs 
for the various groups Antibody levels of ~ 35 mIU ml- 1 
at month 1 probably reflect the first dose of HBIg in 
groups 1-4 Tltres rose to about 45 mIU ml-a at month 
2 for women receiving two doses of HBIg and vaccine 
At month 4, after two doses of HBIg and vaccine, the 
GMTs for groups 3 and 4 were 16 and 19 mIU ml -~ 
antl-HBs, respectively A significant increase in antl-HBs 
was not observed until after the booster dose was given 
At month 7 the geometric mean tltres of antl-HBs wcre 
significantly lower for all IVF groups compared with 
their control groups (group 1 and 2 versus 5 p<0 05, 
g roup3and4versus6  p<0001)  
Since selection of vacclnees due to loss to follow-up 
may have occurred, the GMT levels of all vacclnees per 
group were compared with the GMTs of those vacclnees 
who completed the full immunization scheme in each 
IVF group No differences in GMTs could be shown at 
any moment 
At month 7 an effect of sex on the immune response 
to hepatitis B vaccine was Indicated by a difference 
between the female and male groups (IVF groups l + 2 
versus 3 +4) The influence of sex was not exhlbtted by 
control groups 5 and 6 During the observation period 
of maximal 7 months antl-HBc seroconverslon did not 
occur in IVF groups All controls were also antl-HBc- 
negative after Immunization 
D ISCUSSION 
Hepatitis B lmmunoglobuhn given after exposure to HBV 
results in prolongation of the incubation period of the 
virus and partial protection 6-s Beneficial effects of 
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postexposure prophylaxis with hepatitis B plasma 
vaccine have also been demonstrated in adults 9-a 
The combination of HBIg and hepatitis B vaccine for 
postexposure prophylaxis has been shown to increase 
protection, meaning fewer chnlcal and HBsAg-posltlve 
Infections, compared with HBIg or HB-vacclne alone ~2-~4 
Still, although the spouses of acute hepatitis B patients 
received HBIg (5 ml) on day 1 and plasma vaccine on 
day 1 and 1 and 6 months later (20/tg, Merck Sharp & 
Dohme), 11% exhibited signs of subcllmcal infection 
(antl-HBc-seroconversmn) at the 3 month examination ~2 
Repeated rejections of HBIg can, however, in the case of 
accidental exposure to HBV malntam protective levels 
of antl-HBs throughout he Incubation period 7 a5 To 
accelerate the active immune response, a vacclnatmn 
schedule with short injection intervals has been proposed 
for postexposure prophylaxis a6 
At the discovery of the HBV epidemic the large 
majority of patients who had undergone m vitro 
fertilization were offered postexposure prophylaxis In 
order to modify the course of the disease an 'intensive' 
schedule of two doses of HBIg and four doses of vaccine 
was offered to the females To prevent infection in males 
the standard ~mmunlzatlon schedule was used with an 
addmonal dose of HBIg at month 1 a2 No HBV 
infections, m particular no antl-HBc-seroconverslon, 
were encountered after the start of passive active 
Immunization, however, the protective ffect of passive 
active immunization in this setting cannot be proven In 
view of the absence of a control group with comparable 
exposure The absence of infections in partners after the 
start of immunization is remarkable smce they may have 
been exposed to HBV for several addmonal days or weeks 
because 34 women were still HBeAg-posltlVe at the start 
of immumzatlon Sexual contact is said to be an 
important mode of transmission ~ is However sexual 
exposure appears to be a less efficient mode of 
transmlssmn compared w~th the percutaneous route and 
the chance that men wdl contract hepatitis B wrus during 
a heterosexual relationship has been estimated to be 
< 5(¼) t2 
The overall comphance of couples possibly exposed to 
HBV appeared to be poor The loss to follow-up may 
have been due to lack of motwatlon since exposure to 
HBV in IVF treatment period 2 had not occurred (groups 
2 and 4) and vacclnees were regularly informed about 
their immune status 
Passive active Immunization of HBsAg-posltlve or 
HBV-negatlve and pregnant vaccmees was practically 
devoid of side-effects It is doubtful whether the abortion 
2 days after initial immunization was Indeed a direct 
adverse effect of immunization The first trimester 
abortion rate after IVF did not differ from that found 
for the period before HBV contamination of the culture 
medium was &scovered 5 In fact, immunization of 
pregnant women in case of high risk for hepatms B 
infection is advocated Despite statements of changes m 
immunity during pregnancy there is little evidence of 
impairment of cellular Immumty in pregnancy The 
ability to respond to HBsAg vaccine appeared to be 
adequate19 
This study provided the opportunity to determine 
whether admlnlstratmn of HBIg and recombinant 
HB-vacclne to adults in a high risk Sltuatmn consistently 
led to protective levels of antl-HBs soon after immuniz- 
ation The first dose of HBIg resulted in a protective level 
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of antl-HBs in all but two cases Subsequent HBIg and 
vaccine doses &d not produce a major Increase in 
antl-HBs levels, except for the booster dose of vaccine 
at month 6 In fact, admlmstratlon of a supplementary 
dose of HBIg at month 4 was thought to be necessary 
for the majority of the spouses of HBsAg-posltlVe women 
The overall response rate to recombinant HB- 
vaccine at month 7 was comparable to the response rate 
for hospital personnel Protective levels of antl-HBs 
before the booster dose were, however, relatively low 
(87% for both female groups and 48% and 81% (mean 
63%) for groups 3 and 4, respectively, at month 6) 
compared with other studies of recombinant vaccine 2°-22 
in which ~>93% of healthy adults had antl-HBs 
>~10mIU m1-1 at the time of the booster dose The 
'intensive' immunization schedule with an extra dose of 
vaccine after 2 months did not appear to accelerate the 
immune response m females In fact, as far as postexposure 
prophylaxis is concerned, lmmunogenlclty after adminis- 
tration of recombinant vaccine was very disappointing 
in this study 
Recently, lwarson recommended an accelerated im- 
munization schedule that would yield a more rapid 
antibody response 16 23 such a schedule might be an 
alternative to HBIg in combination w~th HB-vacclne in 
the postexposure situation This study, with a vaccine 
schedule of 0, 2 and 6 weeks, did not yield satisfactory 
antibody levels at all, thus emphasizing the need for HBIg 
in postexposure prophylaxis 
Known factors that influence the immune response to 
vaccine include age, sex, antigen dose and number of 
doses given, site of injection and freezing of the 
vacclne24 25 Sex-related ifferences in immune response 
were found for the combined IVF groups but not for 
controls Age, dose, site of lnjectmn and vaccine were the 
same for the IVF groups and controls Could the large 
doses of HBIg have interfered with the development of 
anti-HBs after immunization9 Studies of the concurrent 
administration of HBIg and plasma derived vaccine at 
one or two occasions howed that the results were similar 
to those obtained with vaccine alone 9 26-28 Szmuness 
et al 2s found that rejection of 300 IU of HBIg did not 
Inhibit the antl-HBs response to 20/tg doses of HB- 
vaccine (Heptavax B, Merck Sharp & Dohme) in 
adults In neonates, two major studies have yielded 
conclusive evidence in favour of the dual approach of 
postexposure prophylaxis by combination of passive 
active immunization la 29 The attack rate for develop- 
ment of the persistent carrier state in neonates of HBeAg- 
positive HBsAg carrier mothers was 90% in untreated 
groups Both HBIg alone or vaccine alone had 70 80% 
efficacy while efficacy rates in the groups given dual 
prophylaxis were above 90% 13 There was no statlstmally 
significant advantage from multiple doses as opposed to 
a single dose of immune globuhn in conjunction w~th 
hepatms B vaccine for efficacy nor for immune response 
(GMT) 29 
Yet, it cannot be excluded with certainty that an 
mhxbmng effect of HBIg was masked by the high dose 
of the vaccine used in these studies To Investigate this 
possible interference, Lehe et al 30 compared the anti- 
HBs response to a low dose (06/~g) of HB heat- 
inactivated vaccine (CLB, 3 ~g per dose) in health-care 
workers with and without a single dose s~multaneously 
administered HBIg (500IU) The antl-HBs tItres of 
recipients of vaccine alone compared with those with 
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HBIg and vaccine were shghtly but stgnlficantly higher 
at 3 and 5 months after the first mjectlons but this 
difference was no longer slgmficant at the t~me of the 
booster dose (month 8) and thereafter 
The use of higher doses of HBIg and the recombmant 
vaccine with a limited epitope range compared with 
plasma HBsAg justifies re-exammation of a possible 
interaction between doses of HBIg and the immune 
response to recombinant vaccine Studies of children 
receiving recombinant vaccme however did not reveal 
significant differences when supplemental HBIg was 
admin is te red  31 
Enwronmental factors have never been known to 
influence the tmmune response to immuntzat]on Never- 
theless, emottons may have an important effect on the 
immune system In rats stress has been shown to 
suppress cellular and humoral immunity 32-3" For 
humans m vt t ro  and m wvo stu&es have demonstrated a 
dtrect effect of psychologtcal stress on parameters of 
immune function 3" 35 Several dtseases caused by wruses, 
such as Epstem-Barr virus, herpes simplex vtrus type 1 
and cytomegalov~rus, may be stress-related 36 The ablhty 
of human lymphocytes to respond to an actwatmg agent 
dechned s~gmficantly wlthm 1 2 months of a serious 
psychological event In some people the responses 
remained low for ,in entire year 3~ 
W~thout doubt parUopatlon in an m t, t t ro  fertilization 
programme and the subsequent discovery of a possible 
lnfectton with hepatitis B virus can be considered an 
episode of stress For the majority of vaccmees the period 
of stress lasted until several months after the first injection 
of vaccme Therefore the effect of psychological stress on 
the human immune response may not be ruled out as a 
posstble factor influencing the reacttvity to HBsAg 
ACKNOWLEDGEMENTS 
The authors are grateful to the nursing staff of the 
Department of Obstetrics of the D0kzlgt Hospital for 
thor cooperation and the technlcmns of the Department 
of V~rology for performing the serological assays 
REFERENCES 
1 Alberda, AT ,  van Os, H C, Zetlmaker, G H, Rothbarth, Ph H, 
Heqtmk, R A and Schalm, S W Hepatitis B-vtrusmfectte blj vrouwen 
behandeld met m wtro fertfl~satte Ned Tqdschr Geneesk 1989, 
133, 20-25 
2 Quint, W G V, de Brutjn, I, Krummg, J and Heijtlnk, R A HBV-DNA 
detecbon by gene amphhcat=on m acute hepatitis B Hepatology 
1990, 12, 653-656 
3 CDC-ACIP Update on hepatitis B prevention Morbid Mortal Week 
Rep 1987, 36, 35,%361 
4 World Health Organization Biological Substances International 
Standards, Reference Preparations and Reference Reagents 
Geneva, Sw=tzerland 1982, pp 70-71 
5 Van Os, HC,  Drogendqk, A C, Fetter, WP F, Heijtmk, RA and 
Zetlmaker, G H The influence of contammabon of the culture- 
medium with hepatitis B virus on the outcome of IVF-pregnanc~es 
Am J Obstet Gynecol 1991, in press 
6 Krugman, S, Overby, L R, Mushawar, I K, Lmg, C M, Frosner, 
G G and Demhardt, F Stud=es on natural history and prevenbon 
re-examined N Engl J Med 1979, 300, 101-106 
7 Grady, G F, Lee, VA,  Pnnce, A Met  al Hepattbs B =mmune 
globuhn for acc=dental exposures among medical personnel final 
report of a multtcenter controlled trial J Infect Dis 1978, 138, 
625~$38 
8 Hoofnagle, J H, Seeff, L B, Bales, Z B, Gerety, R J and Tabor, E 
Passwe-actwe =mmuntty from hepatlt=s B ~mmune globuhn re- 
analys=s of a Veterans Administration Cooperatwe study of 
needle-sbck hepatitis Ann Intern Med 1979, 91,813-818 
9 Szmuness, W, Stevens, C E, Zang, E A, Harley, E J and Kellner, A 
A controlled chmcal trial of the efficacy of the hepabbs B vaccines 
(Heptavax B) A final report Hepatology 1981, 1,377~.q85 
10 Franos, D P, Hadler, S C, Thompson, S Eet  al The prevention of 
hepatitis B with vaccine report of the Centers of Disease Control 
multl-centerefflcacytnalamong homosexual men Ann Intern Med 
1982, 97, 362-366 
11 Szmuness, W, Stevens, C E, Harley, E J et al Hepatitis B vaccine 
in medical staff of hemodlalysts umts effmcacy and sub-type 
cross-protection N Engl J Med 1982, 307, 1481-1487 
12 Papaevangelou, G, Roumehotou-Krayanms, A, Richardson, S C 
and Krugman, S Postexposure ~mmunoprophylaxts of spouses of 
patients with acute vwal hepatitis B Viral Hepatitis B and Liver 
Disease (Ed Zuckerman, A J ) Alan R Liss, Inc, New York, 1988, 
pp 992-994 
13 Beasley, R P, Hwang, LY,  Lee, GCY,  Lan, CC,  Roan, CH,  
Huang, F Y and Chen, C L Prevention of pennatally transmitted 
hepattbs B virus refections wflh hepabtis B immunoglobuhn and 
hepatflls B vaccine Lancet 1983, u, 1099-1102 
14 MItsul, T, Iwano, K, Suzuki, S etal Combined hepabbs B immune 
globuhn and vaccine for postexposure prophylaxis of acodental 
hepatlbs B wrus refection m hemodlalysJs staff members com- 
par=son wflh immune globuhn without vaccine m historical controls 
Hepatology 1989, 10, 324-327 
15 Beasley, R P, Hwang, LY,  Lm, CC et al Hepabtms B immune 
globuhn (HBIG) efficacy in the interruption of permatal transmission 
of hepabbs B virus carner state imtlal report of a randomtsed 
double-bhnd placebo controlled trial Lancet 1981, ti, 388-393 
16 Wahl, M, Hermodsson, S and Iwarson, S Hepatitis B vaccination 
with short dose intervals - a possfble alternatwe for post-exposure 
prophylaxis 9 Infection 1988, 16, 229-232 
17 Daram, M and Gerber, M Hepabbs B anbgen in vaginal secrebons 
Lancet 1974, ii, 1008 
18 Papaevangelou, G, Roumehotou-Karayanms, A Tassopoulos, N 
KolmtJs, N and Stathopoulou, P Source of mfecbon due to hepabbs 
B virus m Greece J Infect Dis 1983, 147, 987-989 
19 Sttrrat G M Immunology of diseases of pregnancy Immunology of 
Pregnancy and its Disorders (Ed Stern, C M H ) Kluwer Academic 
London 1989, pp 115 143 
20 Holhnger, F B, Trolsl, C L and Pepe, P E AntiHBs responses to 
vaccmabon wflh a human hepabtts B vaccine made by recombinant 
DNA technology in yeast J Infect Dis 1986, 153, 156-159 
21 Jflg, W, Schmtdt, M, Zoulek, G, Lorbeer, B, Wflske, B and 
Demhardt, F Chntcal evaluation of a recombmant hepatfl~s B 
vaccine Lancet 1984, it, 1174-1175 
22 Heljtlnk, R A, Krummg, J, Bakker, M and Schalm, SW Immune 
response after vaccination with recombinant vaccine Anttvlral Res 
1985, Suppl I, 281 288 
23 Iwarson, S Post-exposure prophylaxis for hepabbs B acbve or 
passweO Lancet 1989, n, 146-148 
24 Dlenstag, J L, Werner, B G, Polk, B G et al Hepatitis B vaccine 
in health care personnel safety, immunogentclty and indicators of 
efficacy Ann Intern Med 1984, 101, 34-40 
25 Shaw, FE Jr, Guess, H A, Roets, J M et al Effect of anatomic 
mjecbon s=te, age and smoking on the immune response to hepatitis 
B vaccmabon Vaccine 1989, 7, 425~430 
26 Zachoval, R, Jilg, W, Lorbeer, B, Schmldt, M and Demhardt, F 
Passive-acbve immumzabon against hepabbs B J Infect Dis 1984, 
150, 112-117 
27 Goudeau, A, Coursaget, P, Barm, F, Dubots, F, Chtron, J-P, Denis, 
F and Diop Mar, I Prevenbon of hepabbs B by acbve and 
passwe-actwe immunization Viral Hepatitis 1981 International 
Symposmm (Eds Szmuness W Alter H J and Maynard, J E) 
Frankhn Instptute Press, Philadelphia, 1982 pp 50~525 
28 Szmuness, W, Stevens, C E, Oleszko, W R et al Passwe-acttve 
~mmumzation against hepabtts B immunogemctty studies m adult 
Americans Lancet 1981, ii, 575-577 
29 Wong, VCW Ip HMH Reesmk, HW et al Prevention of the 
HBsAg carrier state m newborn infants of mothers who are chronic 
carriers of HBsAg and HBeAg by administration of hepat=tJs B 
vaccine and hepabtfs B rmmunoglobuhn Lancet 1984, i, 921 926 
30 Lehe, P N, Reeslnk, H W, Grt)m, R, de Jong-van Manen, S Th and 
Reermk-Brongers, E E Samultaneous passwe and acbve tmmumz- 
atlon against hepatitis B Non-interference of hepabtls B immune 
globuhn with the anbHBs response to reduced doses of heat- 
mactwated hepabbs B vaccine Hepatology 1986, 6, 971-975 
31 Stevens, C E, Taylor, P E, Tong, M Je t  al Yeast-recombinant 
hepatlbs B vaccine Efficacy with hepabbs B immune globuhn in 
prevention of pennatal hepabtis B wrus transmission J Am 
686 Vaccine, Vol 9, September  1991 
Med Assoc 1987, 267, 2612-2616 
32 Keller, S E, Weiss, J M, Schlelfer, S J, Miller, N E and Stein, M 
Suppression of immumty by stress effect of graded series of stress 
on lymfocyte stimulation in the rat Sctence 1981, 213, 1397-1400 
33 Balheux, R E Stress and immune response parameters and 
markers Breakdown In human adaptation to "stress Towards a 
multldlsclphnary approach (Eds Balheux, R E, Fielding, F J and 
rAbbate, A) Martlnus Nijhof( Publishers, The Hague, 1984, 
pp 732 739 
34 Rose, N R, Friedman, H and Fahey, J L (Eds) Manual of chmcal 
laboratory immunology, American Society (Microbiology) Wash- 
Hepatitis B prophylaxts ~n IVF women P M Groshelde et al 
ington, DC, 1986 
35 Klecolt-Glaser, J K, Garner, W, Speicher, C, Penn, G M, Holhday, 
J and Glaser, R Psychosoclal modifiers of immunocornpetence m
medical students Psychosom Med 1984, 46, 7 14 
36 Glaser, R, Klecolt-Glaser, J K, Spelcher, C E and Holhday, J E 
Stress, Ionehness and changes in herpes wrus latency J Behav 
Med 1985, 8, 249-260 
37 Marx J L The immune system 'belongs in the body" Pervasive 
anatomical and biochemical links between the immune and nervous 
systems help explain how mood might influence disease susceptl- 
bihty Science 1985, 227, 1190-1193 
Vaccine, Vol 9, September 1991 687 
